Newamsterdam Pharma Company N.V. WT (NAMSW)

$8.90 +0.26 (3.01%)
Market Cap N/A
Revenue (ttm) 14.09M
Net Income (ttm) -176.94M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 500
Avg Vol 4,306
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 46%
Beta N/A
Analysts Strong Sell
Price Target N/A

Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease...

Phone: 31 35 206 2971
Address:
Gooimeer 2-35, Naarden, Netherlands
Latest News on NAMSW
NewAmsterdam Pharma Company Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 8:15 PM EDT - 14 hours ago

NewAmsterdam Pharma Company Transcript: Bank of America Global Healthcare Conference 2026

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May

May 11, 2026, 8:41 AM EDT - 2 days ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May

NewAmsterdam Pharma Company Transcript: Investor update

May 7, 2026, 8:00 AM EDT - 6 days ago

NewAmsterdam Pharma Company Transcript: Investor update

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

May 7, 2026, 7:00 AM EDT - 6 days ago

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 1, 2026, 4:57 PM EDT - 11 days ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma Company Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 13, 2026, 11:45 AM EDT - 4 weeks ago

NewAmsterdam Pharma Company Transcript: 25th Annual Needham Virtual Healthcare Conference

NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference

Apr 8, 2026, 8:00 AM EDT - 5 weeks ago

NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference

NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session

Mar 23, 2026, 8:00 AM EDT - 7 weeks ago

NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session

NewAmsterdam Pharma initiated with a Buy at Truist

2026-03-18T19:50:17.000Z - 7 weeks ago

NewAmsterdam Pharma initiated with a Buy at Truist

NewAmsterdam Pharma Company Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 8:40 AM EDT - 2 months ago

NewAmsterdam Pharma Company Transcript: Leerink Global Healthcare Conference 2026

NewAmsterdam Pharma Company Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 10:30 AM EST - 2 months ago

NewAmsterdam Pharma Company Transcript: TD Cowen 46th Annual Health Care Conference

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

Feb 25, 2026, 8:00 AM EST - 2 months ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

NewAmsterdam Pharma price target raised to $45 from $41 at Guggenheim

2026-02-19T12:25:00.000Z - 2 months ago

NewAmsterdam Pharma price target raised to $45 from $41 at Guggenheim

NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update

Feb 18, 2026, 7:00 AM EST - 3 months ago

NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update

NewAmsterdam Pharma Company Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 11, 2026, 8:30 AM EST - 3 months ago

NewAmsterdam Pharma Company Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit

Feb 4, 2026, 8:00 AM EST - 3 months ago

NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit

NewAmsterdam Pharma price target raised to $47 from $44 at RBC Capital

2026-01-21T11:41:16.000Z - 4 months ago

NewAmsterdam Pharma price target raised to $47 from $44 at RBC Capital

NewAmsterdam Pharma highlights 2025 achievements, 2026 priorities

2026-01-09T13:10:50.000Z - 4 months ago

NewAmsterdam Pharma highlights 2025 achievements, 2026 priorities

NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities

Jan 9, 2026, 8:00 AM EST - 4 months ago

NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities

NewAmsterdam Pharma Company Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 4, 2025, 8:00 AM EST - 5 months ago

NewAmsterdam Pharma Company Transcript: Piper Sandler 37th Annual Healthcare Conference

NewAmsterdam Pharma Company Transcript: Citi Annual Global Healthcare Conference 2025

Dec 3, 2025, 3:15 PM EST - 5 months ago

NewAmsterdam Pharma Company Transcript: Citi Annual Global Healthcare Conference 2025

NewAmsterdam Pharma Company Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 3:50 PM EST - 5 months ago

NewAmsterdam Pharma Company Transcript: Evercore ISI 8th Annual HealthCONx Conference

NewAmsterdam Pharma price target raised to $37 from $30 at Goldman Sachs

2025-12-02T11:41:05.000Z - 5 months ago

NewAmsterdam Pharma price target raised to $37 from $30 at Goldman Sachs

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December

Nov 25, 2025, 8:00 AM EST - 6 months ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December

NewAmsterdam Pharma Company Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 7:00 AM EST - 6 months ago

NewAmsterdam Pharma Company Transcript: Jefferies London Healthcare Conference 2025

NewAmsterdam Pharma Company Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 8:00 AM EST - 6 months ago

NewAmsterdam Pharma Company Transcript: Stifel 2025 Healthcare Conference

NewAmsterdam Pharma Company Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 10:30 AM EST - 6 months ago

NewAmsterdam Pharma Company Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

Nov 5, 2025, 8:00 AM EST - 6 months ago

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November

Oct 30, 2025, 8:00 AM EDT - 6 months ago

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November

NewAmsterdam Pharma assumed with a Buy at H.C. Wainwright

2025-10-20T10:20:42.000Z - 7 months ago

NewAmsterdam Pharma assumed with a Buy at H.C. Wainwright

NewAmsterdam Pharma price target raised to $50 from $42 at Citi

2025-10-17T10:20:31.000Z - 7 months ago

NewAmsterdam Pharma price target raised to $50 from $42 at Citi

NewAmsterdam Pharma Company Transcript: Stifel Virtual Cardiometabolic Forum

Sep 30, 2025, 11:00 AM EDT - 8 months ago

NewAmsterdam Pharma Company Transcript: Stifel Virtual Cardiometabolic Forum

NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum

Sep 24, 2025, 8:00 AM EDT - 8 months ago

NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum

NewAmsterdam Pharma Company Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 5, 2025, 10:15 AM EDT - 8 months ago

NewAmsterdam Pharma Company Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

NewAmsterdam Pharma Company Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 2:45 PM EDT - 8 months ago

NewAmsterdam Pharma Company Transcript: Cantor Global Healthcare Conference 2025

NewAmsterdam Pharma Company Transcript: Citi's Biopharma Back to School Conference

Sep 3, 2025, 2:30 PM EDT - 8 months ago

NewAmsterdam Pharma Company Transcript: Citi's Biopharma Back to School Conference

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September

Aug 25, 2025, 8:00 AM EDT - 9 months ago

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September

NewAmsterdam Pharma initiated with an Overweight at Wells Fargo

2025-08-25T09:55:09.000Z - 9 months ago

NewAmsterdam Pharma initiated with an Overweight at Wells Fargo

Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site

Aug 21, 2025, 2:41 AM EDT - 9 months ago

Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site

NewAmsterdam announces acceptance of MAA for review by EMA for obicetrapib

2025-08-18T12:20:58.000Z - 9 months ago

NewAmsterdam announces acceptance of MAA for review by EMA for obicetrapib

NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib

Aug 18, 2025, 8:00 AM EDT - 9 months ago

NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

Aug 6, 2025, 7:00 AM EDT - 10 months ago

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

NewAmsterdam Pharma Company Transcript: Status Update

Jul 30, 2025, 10:00 AM EDT - 10 months ago

NewAmsterdam Pharma Company Transcript: Status Update

NewAmsterdam Pharma presents data from BROADWAY trial at AAIC

2025-07-30T12:30:16.000Z - 10 months ago

NewAmsterdam Pharma presents data from BROADWAY trial at AAIC

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025

Jul 30, 2025, 8:25 AM EDT - 10 months ago

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025

NewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025

Jul 22, 2025, 8:00 AM EDT - 10 months ago

NewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025

NewAmsterdam Pharma initiated with a Neutral at Goldman Sachs

2025-07-17T10:36:20.000Z - 10 months ago

NewAmsterdam Pharma initiated with a Neutral at Goldman Sachs

NewAmsterdam Pharma Company Transcript: R&D Day 2025

Jun 11, 2025, 9:00 AM EDT - 1 year ago

NewAmsterdam Pharma Company Transcript: R&D Day 2025

NewAmsterdam Pharma Company Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 2:40 PM EDT - 1 year ago

NewAmsterdam Pharma Company Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial

Jun 9, 2025, 7:00 AM EDT - 1 year ago

NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial

NewAmsterdam Pharma to Host R&D Day on June 11, 2025

Jun 5, 2025, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma to Host R&D Day on June 11, 2025

NewAmsterdam Pharma Company Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 10:30 AM EDT - 1 year ago

NewAmsterdam Pharma Company Transcript: Jefferies Global Healthcare Conference 2025

NewAmsterdam Pharma Company Transcript: 45th Annual William Blair Growth Stock Conference

Jun 3, 2025, 4:20 PM EDT - 1 year ago

NewAmsterdam Pharma Company Transcript: 45th Annual William Blair Growth Stock Conference

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

May 27, 2025, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference

May 14, 2025, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

May 7, 2025, 7:15 AM EDT - 1 year ago

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

Apr 30, 2025, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

NewAmsterdam Pharma Company Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 7, 2025, 12:45 PM EDT - 1 year ago

NewAmsterdam Pharma Company Transcript: 24th Annual Needham Virtual Healthcare Conference

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

NewAmsterdam Pharma Company Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Company Transcript: Leerink Global Healthcare Conference 2025

NewAmsterdam Pharma Company Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 1:50 PM EST - 1 year ago

NewAmsterdam Pharma Company Transcript: TD Cowen 45th Annual Healthcare Conference

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

Feb 26, 2025, 8:00 AM EST - 1 year ago

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

NewAmsterdam Pharma Company Transcript: Guggenheim SMID Cap Biotech Conference

Feb 5, 2025, 10:00 AM EST - 1 year ago

NewAmsterdam Pharma Company Transcript: Guggenheim SMID Cap Biotech Conference

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Dec 13, 2024, 5:16 PM EST - 1 year ago

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 11, 2024, 9:37 PM EST - 1 year ago

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 10, 2024, 4:34 PM EST - 1 year ago

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma Company Transcript: Status Update

Dec 10, 2024, 8:00 AM EST - 1 year ago

NewAmsterdam Pharma Company Transcript: Status Update

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

Dec 10, 2024, 7:00 AM EST - 1 year ago

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

NewAmsterdam Pharma Company Transcript: Jefferies London Healthcare Conference 2024

Nov 21, 2024, 8:00 AM EST - 1 year ago

NewAmsterdam Pharma Company Transcript: Jefferies London Healthcare Conference 2024

NewAmsterdam Pharma Company Transcript: Study Update

Nov 20, 2024, 8:10 AM EST - 1 year ago

NewAmsterdam Pharma Company Transcript: Study Update

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

Nov 18, 2024, 3:20 PM EST - 1 year ago

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November

Oct 28, 2024, 4:30 PM EDT - 1 year ago

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November

NewAmsterdam Pharma Company Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 3:40 PM EDT - 1 year ago

NewAmsterdam Pharma Company Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September

Aug 30, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September

NewAmsterdam Pharma Company Transcript: Study Update

Jul 29, 2024, 8:30 AM EDT - 1 year ago

NewAmsterdam Pharma Company Transcript: Study Update

NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024

Jul 26, 2024, 4:01 PM EDT - 1 year ago

NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors

Jul 8, 2024, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors

NewAmsterdam Pharma Company Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 10, 2024, 10:40 AM EDT - 2 years ago

NewAmsterdam Pharma Company Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

NewAmsterdam Pharma Company Transcript: Jefferies 2024 Global Healthcare Conference

Jun 5, 2024, 3:00 PM EDT - 2 years ago

NewAmsterdam Pharma Company Transcript: Jefferies 2024 Global Healthcare Conference

NewAmsterdam Pharma Company Transcript: R&D Day

May 16, 2024, 9:00 AM EDT - 2 years ago

NewAmsterdam Pharma Company Transcript: R&D Day

NewAmsterdam Pharma Company Transcript: 2024 RBC Capital Markets Global Healthcare Conference

May 14, 2024, 4:35 PM EDT - 2 years ago

NewAmsterdam Pharma Company Transcript: 2024 RBC Capital Markets Global Healthcare Conference

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease

Apr 9, 2024, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease

BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors

Apr 9, 2024, 8:00 AM EDT - 2 years ago

BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer

Apr 1, 2024, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer

NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress

Mar 25, 2024, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress

NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD

Mar 12, 2024, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD

NewAmsterdam Pharma Company Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 11, 2024, 4:00 PM EDT - 2 years ago

NewAmsterdam Pharma Company Transcript: Leerink Partners Global Biopharma Conference 2024

NewAmsterdam Pharma Company Transcript: TD Cowen 44th Annual Health Care Conference 2024

Mar 4, 2024, 2:10 PM EST - 2 years ago

NewAmsterdam Pharma Company Transcript: TD Cowen 44th Annual Health Care Conference 2024

NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Feb 28, 2024, 8:00 AM EST - 2 years ago

NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update

NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2024, 10:40 PM EST - 2 years ago

NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2024, 4:01 PM EST - 2 years ago

NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma Company Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Feb 7, 2024, 1:00 PM EST - 2 years ago

NewAmsterdam Pharma Company Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Feb 1, 2024, 4:01 PM EST - 2 years ago

NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

NewAmsterdam Pharma Announces 2024 Strategic Priorities

Jan 4, 2024, 8:00 AM EST - 2 years ago

NewAmsterdam Pharma Announces 2024 Strategic Priorities

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights

Nov 13, 2023, 8:00 AM EST - 2 years ago

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights

NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer

Oct 23, 2023, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer

Tessellate BIO Emerges from Stealth

Oct 17, 2023, 3:00 AM EDT - 2 years ago

Tessellate BIO Emerges from Stealth

REPL

NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer's Disease Who Carry an ApoE4 Mutation

Sep 21, 2023, 7:00 AM EDT - 2 years ago

NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer's Disease Who Carry an ApoE4 Mutation